CA2353574C
(fr)
*
|
1998-12-07 |
2012-05-08 |
Zheng Xin Dong |
Analogues du glp-1
|
ATE394423T1
(de)
|
1998-12-07 |
2008-05-15 |
Sod Conseils Rech Applic |
Analoge des glucagon ähnlichen peptides-1 (glp-1)
|
BR0113178A
(pt)
*
|
2000-08-02 |
2004-04-06 |
Theratechnologies Inc |
Peptìdeos biológicos modificados com potência aumentada
|
US7371721B2
(en)
|
2000-09-18 |
2008-05-13 |
Sanos Bioscience A/S |
Use of GLP-2 and related compounds for the treatment, prevention, diagnosis, and prognosis of bone-related disorders and calcium homeostasis related syndromes
|
EP1970072A1
(fr)
|
2000-09-18 |
2008-09-17 |
Sanos Bioscience A/S |
Utilisation de peptides GLP-2 pour le traitement d'hyperparathyroïdie
|
US7186683B2
(en)
|
2000-09-18 |
2007-03-06 |
Sanos Bioscience A/S |
Use of GLP for the treatment, prevention, diagnosis, and prognosis of bone-related and nutrition-related disorders
|
DE60136958D1
(de)
|
2000-12-01 |
2009-01-22 |
Takeda Pharmaceutical |
Verfahren zur herstellung einer zubereitung mit einer bioaktiven substanz
|
GB0100196D0
(en)
*
|
2001-01-04 |
2001-02-14 |
Anmat Technology Ltd |
Peptides
|
EP1411968B1
(fr)
*
|
2001-07-31 |
2008-09-17 |
THE GOVERNMENT OF THE UNITED STATES OF AMERICA, as represented by THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES |
Glp-1, exendine-4, analogues peptidiques et utilisations associees
|
US7238671B2
(en)
|
2001-10-18 |
2007-07-03 |
Bristol-Myers Squibb Company |
Human glucagon-like-peptide-1 mimics and their use in the treatment of diabetes and related conditions
|
MXPA04003553A
(es)
*
|
2001-10-18 |
2004-07-22 |
Bristol Myers Squibb Co |
Mimeticos del peptido-1 similares aglucagon humano y su uso en tratamiento de diabetes y condiciones relacionadas.
|
US7332819B2
(en)
*
|
2002-01-09 |
2008-02-19 |
Micron Technology, Inc. |
Stacked die in die BGA package
|
AU2003271452A1
(en)
*
|
2002-09-25 |
2004-04-19 |
Theratechnologies Inc. |
Modified glp-1 peptides with increased biological potency
|
CN100354306C
(zh)
*
|
2002-10-11 |
2007-12-12 |
株式会社三和化学研究所 |
Glp-1衍生物及其经粘膜吸收的制剂
|
US7731947B2
(en)
|
2003-11-17 |
2010-06-08 |
Intarcia Therapeutics, Inc. |
Composition and dosage form comprising an interferon particle formulation and suspending vehicle
|
WO2004074315A2
(fr)
*
|
2003-02-19 |
2004-09-02 |
Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) |
Analogues de glp-1
|
AU2004225649B2
(en)
*
|
2003-03-28 |
2008-11-06 |
National Institute Of Agrobiological Sciences |
Process for producing plant storage organ with high production of recombinant protein and novel recombinant protein
|
DE10314610A1
(de)
|
2003-04-01 |
2004-11-04 |
Aventis Pharma Deutschland Gmbh |
Neues Diphenylazetidinon mit verbesserten physiologischen Eigenschaften, Verfahren zu dessen Herstellung, diese Verbindungen enthaltende Arzneimittel und dessen Verwendung
|
CN1812808B
(zh)
|
2003-06-03 |
2012-07-04 |
诺沃挪第克公司 |
稳定化的药物肽组合物
|
CN102940879B
(zh)
|
2003-06-03 |
2017-06-06 |
诺沃挪第克公司 |
稳定化的药物肽组合物
|
US7094800B2
(en)
|
2003-07-25 |
2006-08-22 |
Sanofi-Aventis Deutschland Gmbh |
Cyanopyrrolidides, process for their preparation and their use as medicaments
|
US7094794B2
(en)
|
2003-07-28 |
2006-08-22 |
Sanofi-Aventis Deutschland Gmbh |
Substituted thiazole-benzoisothiazole dioxide derivatives, process for their preparation and their use
|
DE10335092B3
(de)
|
2003-08-01 |
2005-02-03 |
Aventis Pharma Deutschland Gmbh |
Substituierte Benzoylureido-o-benzoylamide, Verfahren zu deren Herstellung und deren Verwendung
|
JP2007536214A
(ja)
*
|
2003-12-16 |
2007-12-13 |
ソシエテ・ドゥ・コンセイユ・ドゥ・ルシェルシュ・エ・ダプリカーション・シャンティフィック・エス・ア・エス |
Glp−1類似体
|
US7521527B2
(en)
|
2003-12-16 |
2009-04-21 |
Societe De Conseils De Recherches Et D'applications Scientifiques, S.A.S. |
GLP-1 pharmaceutical compositions
|
CA2549582A1
(fr)
*
|
2003-12-18 |
2005-06-30 |
Novo Nordisk A/S |
Nouveaux composes de glp-1
|
CA2552526A1
(fr)
*
|
2004-01-08 |
2005-07-21 |
Theratechnologies Inc. |
Analogues peptidiques 1 semblables au glucagon a action de longue duree
|
CN101010339B
(zh)
*
|
2004-07-02 |
2011-11-09 |
布里斯托尔-迈尔斯斯奎布公司 |
人类胰高血糖素样肽-1调节剂及它们在治疗糖尿病及相关病况中的用途
|
TW200611704A
(en)
*
|
2004-07-02 |
2006-04-16 |
Bristol Myers Squibb Co |
Human glucagon-like-peptide-1 modulators and their use in the treatment of diabetes and related conditions
|
EP2330126B1
(fr)
|
2004-10-07 |
2015-12-23 |
Novo Nordisk A/S |
Composés d'exendin-4 à effet prolongé
|
JP2008515856A
(ja)
|
2004-10-07 |
2008-05-15 |
ノボ ノルディスク アクティーゼルスカブ |
遅延性glp−1化合物
|
EP1841448A2
(fr)
|
2004-12-30 |
2007-10-10 |
Diakine Therapeutics, Inc. |
Compositions pharmaceutiques et procedes pour le retablissement de masse et de fonction de cellule-beta
|
WO2006083761A2
(fr)
|
2005-02-03 |
2006-08-10 |
Alza Corporation |
Solutions de solvant/polymere utilisees comme vehicules de suspension
|
US11246913B2
(en)
|
2005-02-03 |
2022-02-15 |
Intarcia Therapeutics, Inc. |
Suspension formulation comprising an insulinotropic peptide
|
TWI372629B
(en)
|
2005-03-18 |
2012-09-21 |
Novo Nordisk As |
Acylated glp-1 compounds
|
KR20070120112A
(ko)
|
2005-03-18 |
2007-12-21 |
노보 노르디스크 에이/에스 |
연장형 glp-1 화합물
|
US20070004616A1
(en)
*
|
2005-06-30 |
2007-01-04 |
Roland Cherif-Cheikh |
GLP-1 pharmaceutical compositions
|
EP1904525A4
(fr)
|
2005-06-30 |
2009-10-21 |
Ipsen Pharma |
Compositions pharmaceutiques de glp-1
|
CA2628241C
(fr)
|
2005-11-07 |
2016-02-02 |
Indiana University Research And Technology Corporation |
Analogues de glucagon a solubilite et a stabilite physiologiques ameliorees
|
JP2009534423A
(ja)
|
2006-04-20 |
2009-09-24 |
アムジェン インコーポレイテッド |
Glp−1化合物
|
DE602007009377D1
(de)
|
2006-05-30 |
2010-11-04 |
Intarcia Therapeutics Inc |
Zweiteiliger flussmodulator mit einem internen kanal für ein osmotisches ausgabesystem
|
BRPI0713575A2
(pt)
*
|
2006-06-23 |
2013-02-13 |
Hoffmann La Roche |
mÉtodo para preparar um peptÍdeo insulinotràpico, fragmento de peptÍdeo, peptÍdeo ou uma contraparte do mesmo
|
GB0612669D0
(en)
*
|
2006-06-27 |
2006-08-09 |
Univ Leeds |
Biomarkers for preeclampsia
|
CA2666193A1
(fr)
|
2006-08-08 |
2008-02-14 |
Sanofi-Aventis |
Imidazolidin-2,4-dione arylaminoaryl-alkyl-substituee, son procede de fabrication, medicament contenant ce compose et son utilisation
|
ES2398126T3
(es)
|
2006-08-09 |
2013-03-13 |
Intarcia Therapeutics, Inc |
Sistemas de liberación osmótica y unidades de pistón
|
EA200900392A1
(ru)
|
2006-09-07 |
2010-06-30 |
Никомед Гмбх |
Комбинированное лечение сахарного диабета
|
JP2010523473A
(ja)
*
|
2006-12-29 |
2010-07-15 |
イプセン ファルマ ソシエテ パール アクシオン サンプリフィエ |
Glp−1医薬組成物
|
RU2445972C2
(ru)
*
|
2006-12-29 |
2012-03-27 |
Ипсен Фарма С.А.С. |
Фармацевтические композиции glp-1
|
DE102007005045B4
(de)
|
2007-01-26 |
2008-12-18 |
Sanofi-Aventis |
Phenothiazin Derivate, Verfahren zu ihrer Herstellung und ihre Verwendung als Arzneimittel
|
NZ578948A
(en)
|
2007-02-15 |
2012-03-30 |
Univ Indiana Res & Tech Corp |
Glucagon/glp-1 receptor co-agonists
|
MX2009011123A
(es)
|
2007-04-23 |
2009-11-02 |
Intarcia Therapeutics Inc |
Formulaciones de suspensiones de peptidos insulinotropicos y sus usos.
|
EP2025674A1
(fr)
|
2007-08-15 |
2009-02-18 |
sanofi-aventis |
Tetrahydronaphthaline substituée, son procédé de fabrication et son utilisation en tant que médicament
|
EP2190872B1
(fr)
|
2007-09-05 |
2018-03-14 |
Novo Nordisk A/S |
Dérivés de glucagon-like peptide-1 et leur utilisation pharmaceutique
|
US20100292133A1
(en)
|
2007-09-05 |
2010-11-18 |
Novo Nordisk A/S |
Truncated glp-1 derivaties and their therapeutical use
|
EP2190460B1
(fr)
|
2007-09-05 |
2014-12-17 |
Novo Nordisk A/S |
Peptides dérivés avec a-b-c-d et utilisation thérapeutique de ceux-ci
|
EP2650006A1
(fr)
*
|
2007-09-07 |
2013-10-16 |
Ipsen Pharma S.A.S. |
Analogues d'exendine-4 et exendine-3
|
DK2205624T3
(da)
|
2007-10-27 |
2017-01-02 |
Corden Pharma Colorado Inc |
Insulinotropisk peptidsyntese under anvendelse af faststof- og opløsningsfasekombinationsteknikker
|
JP5771005B2
(ja)
|
2007-10-30 |
2015-08-26 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーションIndiana University Research And Technology Corporation |
グルカゴンアンタゴニスト及びglp−1アゴニスト活性を示す化合物
|
DE102007054497B3
(de)
|
2007-11-13 |
2009-07-23 |
Sanofi-Aventis Deutschland Gmbh |
Neue kristalline Diphenylazetidinonhydrate und Verfahren zu deren Herstellung
|
KR20100102652A
(ko)
*
|
2007-12-11 |
2010-09-24 |
에프. 호프만-라 로슈 아게 |
고체- 및 용액-상 조합 기법을 사용한 인슐린친화성 펩타이드 합성
|
DK2240155T3
(da)
|
2008-02-13 |
2012-09-17 |
Intarcia Therapeutics Inc |
Indretninger, formuleringer og fremgangsmåder til levering af flere gavnlige midler
|
PE20100056A1
(es)
*
|
2008-06-17 |
2010-01-26 |
Univ Indiana Res & Tech Corp |
Analogos de glucagon como agonistas gip
|
AR072160A1
(es)
|
2008-06-17 |
2010-08-11 |
Univ Indiana Res & Tech Corp |
Co-agonistas del receptor de glucagon/glp-1
|
EP4074327A1
(fr)
|
2008-06-27 |
2022-10-19 |
Duke University |
Agents thérapeutiques comprenant des peptides de type élastine
|
CA2733200A1
(fr)
|
2008-08-06 |
2010-02-11 |
Novo Nordisk Health Care Ag |
Proteines conjuguees a efficacite in vivo prolongee
|
KR20110043689A
(ko)
*
|
2008-08-07 |
2011-04-27 |
입센 파마 에스.에이.에스 |
N-말단이 변형된 포도당 의존적인 인슐린 분비 자극성 폴리펩타이드(gip)의 유사체
|
CN103641906A
(zh)
*
|
2008-08-07 |
2014-03-19 |
益普生制药股份有限公司 |
葡萄糖依赖性促胰岛素多肽类似物
|
EA020019B1
(ru)
*
|
2008-08-07 |
2014-08-29 |
Ипсен Фарма С.А.С. |
Аналоги глюкозозависимого инсулинотропного полипептида
|
CN102170896A
(zh)
*
|
2008-08-07 |
2011-08-31 |
益普生制药股份有限公司 |
糖依赖性胰岛素释放肽的截短类似物
|
TW201012829A
(en)
*
|
2008-09-22 |
2010-04-01 |
Ipsen Mfg Ireland Ltd |
Process for the synthesis of (Aib8,35)hGLP-1(7-36)-NH2
|
AU2008365559B2
(en)
*
|
2008-12-15 |
2016-02-25 |
Zealand Pharma A/S |
Glucagon analogues
|
BRPI0823379A2
(pt)
|
2008-12-15 |
2015-07-14 |
Zealand Pharma As |
Análogos de glucagon
|
EA020537B1
(ru)
|
2008-12-15 |
2014-11-28 |
Зилэнд Фарма А/С |
Аналоги глюкагона
|
ES2477880T3
(es)
|
2008-12-15 |
2014-07-18 |
Zealand Pharma A/S |
Análogos del glucagón
|
JP2012512903A
(ja)
|
2008-12-19 |
2012-06-07 |
インディアナ ユニバーシティー リサーチ アンド テクノロジー コーポレーション |
アミド系グルカゴンスーパーファミリーペプチドプロドラッグ
|
CA2747309C
(fr)
|
2008-12-23 |
2023-09-26 |
F. Hoffmann-La Roche Ag |
Procede de tests structures de diagnostic ou d'aide a la therapie pour un patient atteint d'une affection chronique, et dispositifs a cet effet
|
US20100183876A1
(en)
*
|
2008-12-23 |
2010-07-22 |
Hell Andre |
Process for the Preparation of a Peptide Powder Form
|
MX2011007736A
(es)
|
2009-01-22 |
2011-09-06 |
Novo Nordisk Healthcare Ag |
Compuestos de hormona del crecimiento estables.
|
EP2216042A1
(fr)
|
2009-02-09 |
2010-08-11 |
Ipsen Pharma S.A.S. |
Compositions pharmaceutiques analogues au GLP-1
|
WO2010125079A2
(fr)
*
|
2009-05-01 |
2010-11-04 |
F. Hoffmann-La Roche Ag |
Synthèse de peptides insulinotropiques à l'aide d'une combinaison de techniques en phase solide et soluble
|
IN2012DN00377A
(fr)
|
2009-06-16 |
2015-08-21 |
Univ Indiana Res & Tech Corp |
|
US9156901B2
(en)
|
2009-07-13 |
2015-10-13 |
Ditte Riber |
Acylated glucagon analogues
|
CN102612376A
(zh)
|
2009-08-06 |
2012-07-25 |
诺沃-诺迪斯克保健股份有限公司 |
具有延长的体内功效的生长激素
|
DK2470552T3
(en)
|
2009-08-26 |
2014-02-17 |
Sanofi Sa |
NOVEL, CRYSTALLINE, heteroaromatic FLUORGLYCOSIDHYDRATER, MEDICINES COVERING THESE COMPOUNDS AND THEIR USE
|
NZ747990A
(en)
|
2009-09-28 |
2020-06-26 |
Intarcia Therapeutics Inc |
Rapid establishment and/or termination of substantial steady-state drug delivery
|
EP2491054A2
(fr)
|
2009-10-22 |
2012-08-29 |
Cadila Healthcare Limited |
Antagoniste des récepteurs du glucagon et agoniste du glp-i actifs par voie orale, à base de peptidomimétiques à chaîne courte
|
JP5875527B2
(ja)
|
2010-01-22 |
2016-03-02 |
ノヴォ・ノルディスク・ヘルス・ケア・アーゲー |
in−vivoにおける効力が延長された成長ホルモン
|
CA2787895A1
(fr)
|
2010-01-22 |
2011-07-28 |
Novo Nordisk Health Care Ag |
Composes stables d'hormone de croissance
|
WO2011094337A1
(fr)
|
2010-01-27 |
2011-08-04 |
Indiana University Research And Technology Corporation |
Conjugués d'antagoniste du glucagon et d'agoniste du gip et compositions pour le traitement de troubles métaboliques et de l'obésité
|
WO2011107494A1
(fr)
|
2010-03-03 |
2011-09-09 |
Sanofi |
Nouveaux dérivés aromatiques de glycoside, médicaments contenants ces composés, et leur utilisation
|
DE102010015123A1
(de)
|
2010-04-16 |
2011-10-20 |
Sanofi-Aventis Deutschland Gmbh |
Benzylamidische Diphenylazetidinone, diese Verbindungen enthaltende Arzneimittel und deren Verwendung
|
CA2793715A1
(fr)
|
2010-04-30 |
2011-11-03 |
Sanwa Kagaku Kenkyusho Co., Ltd. |
Peptide permettant d'ameliorer la stabilite in vivo d'une substance physiologiquement active ou analogues et substance physiologiquement active et analogues presentant une amelioration de la stabilite in vivo
|
EP2582709B1
(fr)
|
2010-06-18 |
2018-01-24 |
Sanofi |
Dérivés d'azolopyridin-3-one en tant qu'inhibiteurs de lipases et de phospholipases
|
US20110313131A1
(en)
|
2010-06-21 |
2011-12-22 |
Christelle Carl |
Reversed phase hplc purification of a glp-1 analogue
|
US8530413B2
(en)
|
2010-06-21 |
2013-09-10 |
Sanofi |
Heterocyclically substituted methoxyphenyl derivatives with an oxo group, processes for preparation thereof and use thereof as medicaments
|
UY33462A
(es)
|
2010-06-23 |
2012-01-31 |
Zealand Pharma As |
Analogos de glucagon
|
CN103068841A
(zh)
*
|
2010-06-24 |
2013-04-24 |
西兰制药公司 |
胰高血糖素类似物
|
TW201215387A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Aventis |
Spirocyclically substituted 1,3-propane dioxide derivatives, processes for preparation thereof and use thereof as a medicament
|
TW201215388A
(en)
|
2010-07-05 |
2012-04-16 |
Sanofi Sa |
(2-aryloxyacetylamino)phenylpropionic acid derivatives, processes for preparation thereof and use thereof as medicaments
|
TW201221505A
(en)
|
2010-07-05 |
2012-06-01 |
Sanofi Sa |
Aryloxyalkylene-substituted hydroxyphenylhexynoic acids, process for preparation thereof and use thereof as a medicament
|
DK3326620T3
(da)
|
2010-12-16 |
2020-05-25 |
Novo Nordisk As |
Faste sammensætninger omfattende en glp-1-agonist og et salt af n-(8-(2- hydroxybenzoyl)amino)caprylsyre
|
WO2012088116A2
(fr)
|
2010-12-22 |
2012-06-28 |
Indiana University Research And Technology Corporation |
Analogues du glucagon présentant une activité de récepteur de gip
|
US20120208755A1
(en)
|
2011-02-16 |
2012-08-16 |
Intarcia Therapeutics, Inc. |
Compositions, Devices and Methods of Use Thereof for the Treatment of Cancers
|
EP2766349B1
(fr)
|
2011-03-08 |
2016-06-01 |
Sanofi |
Dérivés d'oxathiazine substitués par des carbocycles ou des hétérocycles, leur procédé de préparation, médicaments contenant ces composés et leur utilisation
|
US8828994B2
(en)
|
2011-03-08 |
2014-09-09 |
Sanofi |
Di- and tri-substituted oxathiazine derivatives, method for the production thereof, use thereof as medicine and drug containing said derivatives and use thereof
|
US8895547B2
(en)
|
2011-03-08 |
2014-11-25 |
Sanofi |
Substituted phenyl-oxathiazine derivatives, method for producing them, drugs containing said compounds and the use thereof
|
WO2012120053A1
(fr)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Dérivés oxathiazine ramifiés, procédé pour leur préparation, utilisation en tant que médicament, agents pharmaceutiques contenant ces dérivés et leur utilisation
|
WO2012120058A1
(fr)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Dérivés d'oxathiazine substitués par des groupes benzyle ou hétérométhylène, leur procédé de production, leur utilisation comme médicament ainsi que produits pharmaceutiques les contenant et leur utilisation
|
WO2012120055A1
(fr)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Dérivés oxathiazine di- et tri-substitués, procédé pour leur préparation, utilisation en tant que médicament, agent pharmaceutique contenant ces dérivés et utilisation
|
US8871758B2
(en)
|
2011-03-08 |
2014-10-28 |
Sanofi |
Tetrasubstituted oxathiazine derivatives, method for producing them, their use as medicine and drug containing said derivatives and the use thereof
|
WO2012120050A1
(fr)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Nouveaux dérivés phényl-oxathiazine substitués, procédé pour leur préparation, médicaments contenant ces composés et leur utilisation
|
WO2012120051A1
(fr)
|
2011-03-08 |
2012-09-13 |
Sanofi |
Dérivés benzyl-oxathiazine substitués avec adamantane ou noradamantane, médicaments contenant ces composés et leur utilisation
|
RU2602601C2
(ru)
|
2011-04-12 |
2016-11-20 |
Ново Нордиск А/С |
Дважды ацилированные производные glp-1
|
RU2014101697A
(ru)
|
2011-06-22 |
2015-07-27 |
Индиана Юниверсити Рисерч Энд Текнолоджи Корпорейшн |
Коагонисты рецепторов глюкагона/glp-1
|
PE20140724A1
(es)
|
2011-06-22 |
2014-07-10 |
Univ Indiana Res & Tech Corp |
Coagonistas del receptor de glucagon/glp-1
|
AU2012286048A1
(en)
|
2011-07-18 |
2014-02-20 |
Arts Biologics A/S |
Long acting luteinizing hormone (LH) compound
|
EP2567959B1
(fr)
|
2011-09-12 |
2014-04-16 |
Sanofi |
Dérivés d'amide d'acide 6-(4-hydroxy-phényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
|
WO2013037390A1
(fr)
|
2011-09-12 |
2013-03-21 |
Sanofi |
Dérivés amides d'acide 6-(4-hydroxyphényl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique en tant qu'inhibiteurs de kinase
|
EP2760862B1
(fr)
|
2011-09-27 |
2015-10-21 |
Sanofi |
Dérivés d'amide d'acide 6-(4-hydroxyphényl)-3-alkyl-1h-pyrazolo[3,4-b]pyridine-4-carboxylique utilisés comme inhibiteurs de kinase
|
HUE042757T2
(hu)
|
2012-03-22 |
2019-07-29 |
Novo Nordisk As |
Szállító szert tartalmazó készítmények és elõállításuk
|
AU2013234496B2
(en)
|
2012-03-22 |
2017-07-27 |
Novo Nordisk A/S |
Compositions of GLP-1 peptides and preparation thereof
|
SG11201407137PA
(en)
|
2012-05-03 |
2014-11-27 |
Zealand Pharma As |
Gip-glp-1 dual agonist compounds and methods
|
CN104302772B
(zh)
|
2012-05-18 |
2017-11-10 |
爱德迪安(北京)生物技术有限公司 |
用于糖尿病治疗的蛋白、蛋白缀合物及其应用
|
US9993430B2
(en)
|
2012-06-20 |
2018-06-12 |
Novo Nordisk A/S |
Tablet formulation comprising semaglutide and a delivery agent
|
US20150157619A1
(en)
|
2012-07-10 |
2015-06-11 |
Takeda Pharmaceutical Company Limited |
Pharmaceutical preparation for injection
|
KR101848303B1
(ko)
|
2012-07-10 |
2018-04-13 |
삼성전자주식회사 |
전력 전송을 제어하기 위한 방법 및 이를 위한 전력 송신기
|
WO2014016300A1
(fr)
|
2012-07-23 |
2014-01-30 |
Zealand Pharma A/S |
Analogues du glucagon
|
TWI608013B
(zh)
|
2012-09-17 |
2017-12-11 |
西蘭製藥公司 |
升糖素類似物
|
IN2015DN03795A
(fr)
|
2012-10-24 |
2015-10-02 |
Inserm Inst Nat De La Santé Et De La Rech Médicale |
|
WO2014077802A1
(fr)
|
2012-11-13 |
2014-05-22 |
Ipsen Pharma S.A.S. |
Procédé de purification d'un analogue de glp-1
|
WO2014077801A1
(fr)
|
2012-11-13 |
2014-05-22 |
Ipsen Pharma S.A.S. |
Procédé de purification pour préparer du tasoglutide de haute pureté
|
US11045523B2
(en)
|
2013-04-05 |
2021-06-29 |
Novo Nordisk Healthcare Ag |
Formulation of growth hormone albumin-binder conjugate
|
US9738697B2
(en)
|
2013-06-23 |
2017-08-22 |
Wisconsin Alumni Research Foundation |
Alpha/beta-polypeptide analogs of glucagon-like peptide-1
|
CN103536907B
(zh)
*
|
2013-07-18 |
2015-10-21 |
上海交通大学医学院附属瑞金医院 |
利拉鲁肽在骨质疏松治疗药物中的应用
|
BR112016008115B1
(pt)
|
2013-10-17 |
2024-03-12 |
Boehringer Ingelheim International Gmbh |
Análogos de glucagon acilados
|
US9988429B2
(en)
|
2013-10-17 |
2018-06-05 |
Zealand Pharma A/S |
Glucagon analogues
|
WO2015067715A2
(fr)
|
2013-11-06 |
2015-05-14 |
Zealand Pharma A/S |
Composés agonistes doubles de gip et glp-1 et procédés associés
|
BR112016009995B1
(pt)
|
2013-11-06 |
2023-04-18 |
Zealand Pharma A/S |
Compostos agonistas triplos glucagon-glp-1-gip
|
WO2015081891A1
(fr)
|
2013-12-06 |
2015-06-11 |
Baikang (Suzhou) Co., Ltd |
Pro-fragments bioréversibles pour médicaments contenant de l'azote et de l'hydroxyle
|
SG10201805039UA
(en)
*
|
2013-12-13 |
2018-07-30 |
Medimmune Ltd |
Protease resistant peptides
|
US10689429B2
(en)
|
2014-04-07 |
2020-06-23 |
Novo Nordisk A/S |
Double-acylated GLP-1 compounds
|
EP3189072B1
(fr)
|
2014-09-05 |
2018-07-18 |
University of Copenhagen |
Peptides analogues du gip
|
US9889085B1
(en)
|
2014-09-30 |
2018-02-13 |
Intarcia Therapeutics, Inc. |
Therapeutic methods for the treatment of diabetes and related conditions for patients with high baseline HbA1c
|
JP6898231B6
(ja)
|
2014-10-29 |
2021-07-28 |
ジーランド ファーマ アクティーゼルスカブ |
Gipアゴニスト化合物及び方法
|
US10426818B2
(en)
|
2015-03-24 |
2019-10-01 |
Inserm (Institut National De La Sante Et De La Recherche Medicale) |
Method and pharmaceutical composition for use in the treatment of diabetes
|
ES2763329T3
(es)
|
2015-04-16 |
2020-05-28 |
Zealand Pharma As |
Análogo de glucagón acilado
|
NZ738102A
(en)
|
2015-06-03 |
2024-02-23 |
Intarcia Therapeutics Inc |
Implant placement and removal systems
|
CN106554409B
(zh)
*
|
2015-09-30 |
2020-04-07 |
天津药物研究院有限公司 |
一种长效胰高血糖素样肽-1类似物及其应用
|
TWI814219B
(zh)
|
2016-05-16 |
2023-09-01 |
美商因塔希亞治療公司 |
升糖素受體選擇性多肽和彼之使用方法
|
USD860451S1
(en)
|
2016-06-02 |
2019-09-17 |
Intarcia Therapeutics, Inc. |
Implant removal tool
|
USD840030S1
(en)
|
2016-06-02 |
2019-02-05 |
Intarcia Therapeutics, Inc. |
Implant placement guide
|
US10835580B2
(en)
|
2017-01-03 |
2020-11-17 |
Intarcia Therapeutics, Inc. |
Methods comprising continuous administration of a GLP-1 receptor agonist and co-administration of a drug
|
US11572399B2
(en)
|
2017-05-31 |
2023-02-07 |
University Of Copenhagen |
Long-acting GIP peptide analogues
|
ES2960687T3
(es)
|
2018-02-02 |
2024-03-06 |
Novo Nordisk As |
Composiciones sólidas que comprenden un agonista del GLP-1 y una sal del ácido n-(8-(2-hidroxibenzoil)amino)caprílico y un lubricante
|
EA202092269A1
(ru)
*
|
2018-03-23 |
2020-12-14 |
Кармот Терапьютикс, Инк. |
Модуляторы сопряженных с g-белком рецепторов
|
EP4364751A2
(fr)
|
2018-04-05 |
2024-05-08 |
Sun Pharmaceutical Industries Limited |
Nouveaux analogues de glp-1
|
WO2019200594A1
(fr)
|
2018-04-19 |
2019-10-24 |
杭州先为达生物科技有限公司 |
Dérivé de glp-1 acylé
|
AU2019357621A1
(en)
|
2018-10-11 |
2021-05-27 |
Intarcia Therapeutics, Inc. |
Human amylin analog polypeptides and methods of use
|
CN109400695B
(zh)
|
2018-10-31 |
2020-06-30 |
中南大学湘雅医院 |
一种多肽的修饰方法及应用
|
EP3891174A1
(fr)
|
2018-12-03 |
2021-10-13 |
Antag Therapeutics ApS |
Analogues peptidiques de gip modifiés
|
WO2022157747A2
(fr)
|
2021-01-25 |
2022-07-28 |
Mylan Ireland Limited |
Compositions peptidiques pharmaceutiques et leurs procédés de préparation
|
CN114621339B
(zh)
*
|
2021-12-28 |
2022-09-23 |
北京惠之衡生物科技有限公司 |
一种长效glp-1衍生物
|
WO2024068848A1
(fr)
|
2022-09-28 |
2024-04-04 |
Zealand Pharma A/S |
Méthodes de traitement de l'obésité
|